The Life Raft Group celebrated GIST Awareness Day 2021 by holding an virtual, interactive Q&A session for SDH-deficient GIST patients with leading experts in the field.
Become a GEM today! Help us continue our programs and services for GIST patients by giving a monthly recurring donation. Every little bit helps us to further research and support GIST patients and caregivers.
June 28th Awards Ceremony registration: https://livingrare.org/rare-impact-awards/ Dr. Jason Sicklick, Blueprint Medicines Among Honorees Released 2/23/21 by NORD The National Organization for Rare Disorders (NORD®) announced this year’s Rare Impact Award honorees. These outstanding [...]
The 2020 GIST award goes to Dr. Thomas Mühlenberg of the University of Duisburg-Essen The GIST Group Switzerland, the support group for patients with gastrointestinal stromal tumor (GIST), has awarded its science prize for [...]
The annual meeting of CTOS (Connective Tissue Oncology Society) will be held virtually this year due to the global pandemic.
Dr. Gina D'Amato, who appeared recently as moderator and contributor for the first Women in Sarcoma discussion panel, recorded a video discussing the use of liquid biopsy in sarcoma on OncTV for OncLive.
En un artículo publicado el 29 de septiembre de 2020 en la revista “JAMA Network Open”, Dr. Jason Sicklick, Moores Cancer Center, UCSD y sus colegas informaron que las pruebas genéticas son costo efectivas y beneficiosas para los pacientes recién diagnosticados con GIST metastásico.
UC San Diego Health released a post today titled, "Genetic Testing Cost Effective for Newly Diagnosed GIST" discussing a new paper published in JAMA Network Open by Moores Cancer Center's Dr. Jason Sicklick and colleagues which covered genetic testing for GIST patients.
Dr. Jonathan Trent, GIST Specialist at Sylvester Cancer Center and Dr. Andrew Rosenberg, also a GIST Specialist at Sylvester, have co-authored a book dedicated to sarcoma diagnosis and management with other sarcoma experts specifically for the purpose of giving oncologists a credible authority to 'go-to' for sarcoma knowledge.
TargetCancer Foundation (TCF) proudly announced today the initiation of the TCF-001 TRACK (Target Rare Cancer Knowledge) Study, an innovative trial that brings advances in precision medicine to people living with rare cancers and their treating physicians, right in their own communities.
